Prevalence of OSA in Patients of ILD

NCT ID: NCT06058052

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-20

Study Completion Date

2024-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the clinical predictors of OSA in patients with ILD

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interstitial lung diseases (ILDs) are a group of heterogeneous disorders characterized by varying degrees of fibrosis and inflammation of lung parenchyma.

Obstructive sleep apnea is a type of sleep disordered breathing characterized by repeated episodes of apnea and hypopnea during sleep due to narrowing or occlusion of the upper airway.

It was found that the prevalence of OSA is as high as 80% among patients with idiopathic pulmonary fibrosis (IPF). Despite this common association, there is limited research in this field. There is great need for further studies to highlight this association and understand the underlying pathophysiological mechanisms implicated in those patients, to ultimately guide the appropriate management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

OSA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presented to Chest Department with interstitial lung disease will be included, screened for OSA.

Exclusion Criteria

* Age: less than 18 years. Unstable patients or need for ICU admission
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hend Mohamed Sayed Mohamed

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed yassen, MD

Role: STUDY_CHAIR

Assiut University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hend saleh, MD

Role: CONTACT

01098988712

Mohamed Khalaf, MD

Role: CONTACT

01026600071

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILD,OSA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Physical Status of OSA Patients
NCT05051514 COMPLETED
The Taiwan OSA Study
NCT07302685 RECRUITING